<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00717652</url>
  </required_header>
  <id_info>
    <org_study_id>ATTGLE0508</org_study_id>
    <nct_id>NCT00717652</nct_id>
  </id_info>
  <brief_title>Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma</brief_title>
  <acronym>melasma</acronym>
  <official_title>Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In The Treatment Of Facial Melasma, Taking As Reference The Product Triluma ® (Hidroquinone, Fluoncinolone And Tretinoin).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is evaluating the clinical activity of the association (tretinoin&#xD;
      + arbutin + triamcinolone) in the treatment of epidermal melasma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The melasma is a common hipermelanosis, acquired, symmetrical, with irregular occurring in&#xD;
      areas such as photo-exposed face, forehead and temples, can affect the eyelids and tion. The&#xD;
      facial regions most affected are: zigomatic (82.4%), parotid (64.7%), front (64.7%), mandible&#xD;
      (35.3%) and nasal (35.3%). The injuries of melasma is variable increase of epidermal melanin&#xD;
      and inflammatory infiltrate of mild to moderate intensity. Treatment with compounds such as&#xD;
      hydroquinone and derivatives, tretinoin, corticosteroids moderate or combination of them all&#xD;
      have shown good results, diminishing the training, reducing the stability and promoting the&#xD;
      destruction of melanocytes. The primary objective of this study is evaluating the clinical&#xD;
      activity of the association (tretinoin + arbutin + triamcinolone) manufactured by Glenmark&#xD;
      Laboratory, and as the comparator drug product Triluma ® (hydroquinone + fluocinolone +&#xD;
      tretinoin), in the treatment of epidermal melasma through parameters of clinical course of&#xD;
      the disease (improves) and its security.&#xD;
&#xD;
      Patients who are included in the study will be randomly and automatically receive one of the&#xD;
      treatments (New association or Triluma ®), which should use for 12 weeks. The products should&#xD;
      be applied in the regions affected once a day, during night.&#xD;
&#xD;
      The evaluation of clinical improvement, as well as security, will be held on periodic visits,&#xD;
      as described below, which will be held the record and supply of medicines to patients.&#xD;
&#xD;
      In each visit, beyond the clinical examination of photographs and large, it filled the Area&#xD;
      and Severity Scale (Melasma Area and Severity Index - MASI), which quantifies the melasma and&#xD;
      will be the main tool of control of clinical improvement.&#xD;
&#xD;
      At the end of the study, data will be compared, showing no inferiority or inferiority of&#xD;
      clinical drug testing in relation to the comparator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Anticipated">July 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone)in the treatment of epidermal melasma.</measure>
    <time_frame>arbutin triamcinolone tretinoin</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>arbutin, tretinoin, triamcinolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triluma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arbutin, tretinoin, triamcinolone</intervention_name>
    <description>arbutin, tretinoin, triamcinolone</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triluma</intervention_name>
    <description>Hydroquinone, Fluoncinolone, Tretinoin</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women adults aged more than 18 years;&#xD;
&#xD;
          -  Patients suffering from melasma Epidermal the face of mild and moderate;&#xD;
&#xD;
          -  Patients who have not done any treatment for melasma in the 3 months preceding the&#xD;
             study;&#xD;
&#xD;
          -  Patients with good mental and physical health;&#xD;
&#xD;
          -  Patients who agree with the purposes of the study and sign the TCLE.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with skin diseases other than melasma, which interfere in clinical evaluation&#xD;
             as hemangiomas and queloides;&#xD;
&#xD;
          -  Patients with melasma skin or mixed;&#xD;
&#xD;
          -  Patients with sensitivity to agents hipopigmentantes;&#xD;
&#xD;
          -  Patients with sensitivity to fotoprotetores;&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding;&#xD;
&#xD;
          -  Patients who, at the discretion doctor, are not able to participate in the study;&#xD;
&#xD;
          -  Patients who have carried out any treatment for melasma in the 3 months preceding the&#xD;
             study&#xD;
&#xD;
          -  Patients who do not agree with the terms described in the Statement of Informed&#xD;
             Consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lal Clinica Pesquisa E Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>S</state>
        <zip>13270000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2008</study_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clinica</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

